CY1119898T1 - Μεθοδοι χορηγησης ενος αναστολεα toy egfr - Google Patents
Μεθοδοι χορηγησης ενος αναστολεα toy egfrInfo
- Publication number
- CY1119898T1 CY1119898T1 CY20181100024T CY181100024T CY1119898T1 CY 1119898 T1 CY1119898 T1 CY 1119898T1 CY 20181100024 T CY20181100024 T CY 20181100024T CY 181100024 T CY181100024 T CY 181100024T CY 1119898 T1 CY1119898 T1 CY 1119898T1
- Authority
- CY
- Cyprus
- Prior art keywords
- administration
- egfr
- methods
- toy
- suspension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
Abstract
Αποκαλύπτονται μέθοδοι για την θεραπεία ενός ασθενούς που έχει καρκίνο με έναν αναστολέα του υποδοχέα του EGFR, ο οποίος απαιτείται ένα ενεργό βήμα αποφυγής ή τροποποίησης της συγχορήγησης τέτοιων φαρμάκων με διαμορφωτές της P-gp. Η παρούσα εφεύρεση αφορά επίσης ένα φάρμακο για θεραπεία ενός ασθενούς που έχει καρκίνο, το οποίο περιλαμβάνει ως δραστικό συστατικό του προϊόντος έναν αναστολέα του EGFR, προσαρμοσμένο για την αποφυγή της συγχορήγησης με επαγωγείς και/ή αναστολείς της P-gp σύμφωνα με τις οδηγίες που προστίθενται στο φάρμακο ή στην συσκευασία του περιέχει το αναφερόμενο φάρμακο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37717710P | 2010-08-26 | 2010-08-26 | |
PCT/US2011/048922 WO2012027445A1 (en) | 2010-08-26 | 2011-08-24 | Methods of administering an egfr inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119898T1 true CY1119898T1 (el) | 2018-06-27 |
Family
ID=44583460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100024T CY1119898T1 (el) | 2010-08-26 | 2018-01-09 | Μεθοδοι χορηγησης ενος αναστολεα toy egfr |
Country Status (16)
Country | Link |
---|---|
US (2) | US20130289056A1 (el) |
EP (1) | EP2608792B1 (el) |
JP (3) | JP2013536244A (el) |
CY (1) | CY1119898T1 (el) |
DK (1) | DK2608792T3 (el) |
EC (1) | ECSP13012523A (el) |
ES (1) | ES2655115T3 (el) |
HR (1) | HRP20180016T1 (el) |
HU (1) | HUE038049T2 (el) |
LT (1) | LT2608792T (el) |
NO (1) | NO2608792T3 (el) |
PL (1) | PL2608792T3 (el) |
PT (1) | PT2608792T (el) |
RS (1) | RS56682B1 (el) |
SI (1) | SI2608792T1 (el) |
WO (1) | WO2012027445A1 (el) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010040020A1 (en) | 2008-10-02 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US20130289056A1 (en) | 2010-08-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Methods of administering an egfr inhibitor |
BR112021010500A2 (pt) * | 2018-11-30 | 2021-08-24 | Beth Israel Deaconess Medical Center, Inc. | Método para reduzir a p-selectina solúvel em um paciente com câncer, método para reduzir ou prevenir a formação de um trombo em um paciente com câncer, método para promover a regressão tumoral em um paciente com câncer, método para estabilizar ou reduzir o câncer metastático em um paciente com câncer, composição farmacêutica para reduzir a p-selectina solúvel em um paciente com câncer, composição farmacêutica para reduzir ou prevenir a formação de um trombo em um paciente com câncer, composição farmacêutica para promover a regressão tumoral em um paciente com câncer e composição farmacêutica para estabilizar ou reduzir câncer metastático em um paciente com câncer |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
TWI231211B (en) * | 2001-05-01 | 2005-04-21 | Abbott Lab | Compositions and methods for enhancing the bioavailability of pharmaceutical agents |
US20030225079A1 (en) | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
DE10307165A1 (de) | 2003-02-20 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20070009533A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism |
EP2340837B1 (en) * | 2005-11-11 | 2017-03-15 | Boehringer Ingelheim International GmbH | Combination treatment of cancer comprising egfr/her2 inhibitors |
CA2629244C (en) * | 2005-11-11 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
PL1981863T3 (pl) | 2006-01-26 | 2013-03-29 | Boehringer Ingelheim Int | Sposób wytwarzania pochodnych chinazoliny podstawionych przez ugrupowanie aminokrotonyloaminowe |
WO2008034776A1 (en) | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
WO2008121467A2 (en) | 2007-02-28 | 2008-10-09 | Dana-Farber Cancer Institute, Inc. | Combination therapy for treating cancer |
PE20100252A1 (es) | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
ES2731901T3 (es) | 2009-07-06 | 2019-11-19 | Boehringer Ingelheim Int | Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo |
US20130289056A1 (en) | 2010-08-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Methods of administering an egfr inhibitor |
-
2011
- 2011-08-24 US US13/817,571 patent/US20130289056A1/en not_active Abandoned
- 2011-08-24 PL PL11752700T patent/PL2608792T3/pl unknown
- 2011-08-24 LT LTEP11752700.2T patent/LT2608792T/lt unknown
- 2011-08-24 NO NO11752700A patent/NO2608792T3/no unknown
- 2011-08-24 EP EP11752700.2A patent/EP2608792B1/en active Active
- 2011-08-24 JP JP2013526123A patent/JP2013536244A/ja active Pending
- 2011-08-24 WO PCT/US2011/048922 patent/WO2012027445A1/en active Application Filing
- 2011-08-24 SI SI201131382T patent/SI2608792T1/en unknown
- 2011-08-24 ES ES11752700.2T patent/ES2655115T3/es active Active
- 2011-08-24 RS RS20171343A patent/RS56682B1/sr unknown
- 2011-08-24 HU HUE11752700A patent/HUE038049T2/hu unknown
- 2011-08-24 PT PT117527002T patent/PT2608792T/pt unknown
- 2011-08-24 DK DK11752700.2T patent/DK2608792T3/en active
-
2013
- 2013-03-25 EC ECSP13012523 patent/ECSP13012523A/es unknown
-
2016
- 2016-06-09 US US15/177,612 patent/US20160287591A1/en not_active Abandoned
- 2016-12-27 JP JP2016252456A patent/JP6541637B2/ja active Active
-
2018
- 2018-01-05 HR HRP20180016TT patent/HRP20180016T1/hr unknown
- 2018-01-09 CY CY20181100024T patent/CY1119898T1/el unknown
-
2019
- 2019-04-19 JP JP2019079787A patent/JP2019147814A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019147814A (ja) | 2019-09-05 |
PL2608792T3 (pl) | 2018-03-30 |
SI2608792T1 (en) | 2018-02-28 |
JP6541637B2 (ja) | 2019-07-10 |
NO2608792T3 (el) | 2018-03-10 |
WO2012027445A1 (en) | 2012-03-01 |
ES2655115T3 (es) | 2018-02-16 |
JP2013536244A (ja) | 2013-09-19 |
EP2608792A1 (en) | 2013-07-03 |
ECSP13012523A (es) | 2013-05-31 |
EP2608792B1 (en) | 2017-10-11 |
HRP20180016T1 (hr) | 2018-02-09 |
US20130289056A1 (en) | 2013-10-31 |
US20160287591A1 (en) | 2016-10-06 |
PT2608792T (pt) | 2018-01-15 |
HUE038049T2 (hu) | 2018-09-28 |
DK2608792T3 (en) | 2018-01-15 |
RS56682B1 (sr) | 2018-03-30 |
LT2608792T (lt) | 2018-01-10 |
JP2017081966A (ja) | 2017-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122687T1 (el) | Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο | |
CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
CY1123571T1 (el) | Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα | |
CY1121065T1 (el) | Αναστολεις ιβατ για την αγωγη ηπατικων νοσων | |
CY1117440T1 (el) | Συτηκτα παραγωγα ιμιδαζολης ως αναστολεις toy ido | |
CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
EA201590693A1 (ru) | Ингибиторы gdf-8 | |
MX2020003174A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. | |
EA202092456A2 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
NZ720736A (en) | Antibody drug conjugates (adcs) with kinesin spindel protein (ksp) | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
MX340090B (es) | Analogos de spliceostatina. | |
EA201690754A1 (ru) | Применение ингибитора pcsk9 для лечения гиперлипидемии | |
CR20120638A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
MX2021000289A (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
EA201691320A1 (ru) | Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов | |
EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
EA201492290A1 (ru) | Составы и способы для вагинальной доставки антипрогестинов | |
EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
MX2015014455A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer. | |
CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
CY1119898T1 (el) | Μεθοδοι χορηγησης ενος αναστολεα toy egfr | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
CY1124041T1 (el) | Συνθεσεις που περιλαμβανουν κυκλοσπορινη |